---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-22-000101"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:12:09.271097+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics Q3 net loss widens to $37.4M on merger costs; cash $75.5M; LSTA1 trials on track

## Summary
- Net loss $37.4M (Q3 2022) vs $6.9M (Q3 2021), driven by merger-related expenses and stock compensation.
- Cash, equivalents and marketable securities $75.5M as of Sept 30, 2022.
- R&D expenses $3.4M (-18% YoY) due to XOWNA FREEDOM trial suspension; G&A $3.9M (+39%) on merger costs.
- LSTA1 Phase 2b ASCEND and Phase 1b/2 CENDIFOX trials on track to complete enrollment late 2023/early 2024.
- HONEDRA (CLI) pre-consultation with PMDA ongoing; XOWNA (CMD) development paused pending strategic partner.

## SEC filing metadata
- accession: 0000320017-22-000101
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001722000101/0000320017-22-000101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001722000101/clbs-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-22-000101
- JSON: https://secwatch.observer/filing/0000320017-22-000101.json
- Plain text: https://secwatch.observer/filing/0000320017-22-000101.txt

## Key facts
- Earnings Releases
  LISATA THERAPEUTICS, INC. reported financial results for three and nine months ended September 30, 2022.
  - Period: three and nine months ended September 30, 2022
  - Result: reported results
  source text: Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the three and nine months ended September 30, 2022 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001722000101/0000320017-22-000101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.